What does “Januvia MOA” mean?
“Januvia MOA” usually refers to the drug’s MOA, or mechanism of action: how Januvia (sitagliptin) works in the body.
How does Januvia (sitagliptin) work?
Januvia is a DPP-4 (dipeptidyl peptidase-4) inhibitor. It blocks the DPP-4 enzyme, which normally breaks down incretin hormones. By inhibiting DPP-4, Januvia increases the levels of active incretins, which helps increase insulin release and decrease glucagon release in a glucose-dependent way. This lowers blood glucose in people with type 2 diabetes.
Why is the effect described as “glucose-dependent”?
Because incretin signaling (and the resulting insulin and glucagon changes) is tied to the current blood glucose level, the drug’s effects tend to be stronger when glucose is higher and weaker when glucose is closer to normal. That is one reason DPP-4 inhibitors are generally associated with a lower risk of hypoglycemia compared with some other diabetes drugs.
What are common “mechanism-of-action” takeaways patients ask next?
Patients often want to know what Januvia does and does not do compared with other diabetes medications:
- Januvia does not directly replace insulin.
- It improves endogenous insulin and glucagon signaling through incretin pathways by inhibiting DPP-4.
How does MOA relate to side effects or risks?
MOA is also relevant when thinking about side effects. Since Januvia’s glucose-lowering effect depends on incretin physiology and is generally glucose-dependent, it typically has less hypoglycemia risk than agents that directly force insulin release. Patients still need to follow prescriber guidance, especially if used with other glucose-lowering therapies.
Sources
No sources were provided in your prompt.